Alpaloritovorelli antibodies

Phase 1Small molecule

Alpaloritovorelli antibodies is one of 3 small molecule programs targeting Disease Progression. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Disease ProgressionNot yet recruiting

Disease ProgressionPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Disease Progression

#DrugCompanyPhaseTrials

BRINEURA

BioMarin Pharmaceutical

Phase 2

1 2

Biltricide

Bayer

Preclinical

1 3

Alpaloritovorelli antibodies

AAnhui Provincial Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Disease Progression

NCT06760676

Clinical

Trials by Indication[1]

Disease Progression1 trial

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

Not yet recruiting·—·Phase 1·NCT06760676·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alpaloritovorelli antibodies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alpaloritovorelli antibodies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alpaloritovorelli antibodies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Anhui Provincial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAnhui Provincial Hospital

Alpaloritovorelli antibodies

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Disease Progression1 trial

References

Drug Info

Quick Facts

Related News